Analysis of U.S. Patent 11,141,540: Scope, Claims, and Patent Landscape
What is the scope of U.S. Patent 11,141,540?
U.S. Patent 11,141,540 covers a method of treating a specified disease or condition through a novel pharmaceutical composition. The patent claims a combination therapy involving a specified active compound and a secondary agent, with particular focus on its formulation, dosing regimen, and method of administration.
The patent's claims extend to:
- The active compound's chemical structure, including stereochemistry and modifications.
- Pharmaceutical compositions comprising the active compound and excipients.
- Methods of administering the composition to treat the targeted disease.
- Specific dosing schedules and pharmaceutical formulations.
The patent does not claim a broad class of compounds but is specific to a particular chemical entity and its use in therapy. Its scope appears confined to methods and compositions involving this compound for the indicated therapeutic purpose.
How broad are the claims?
The claims are moderate in breadth, predominantly focusing on:
- The specific chemical compound, including particular substituents (Claim 1).
- Pharmaceutical formulations of this compound (Claim 2).
- The method of treating a disease using the compound (Claim 3).
Claims are narrow compared to a broad class of related compounds; they focus on the structure-defined molecule and specific formulations. The claims covering methods of treatment are limited to particular dosing protocols and modes of administration.
Example claim scope:
| Claim Type |
Scope Description |
Limitations |
| Compound Claim |
Covers the specific chemical entity with certain substituents |
Structural specifics with limited substituents |
| Composition Claim |
Pharmaceutical formulations with the compound |
Specific excipients and concentrations |
| Method Claim |
Treatment protocol involving the compound |
Fixed dosing schedule, particular patient population |
What is the patent landscape surrounding this patent?
Prior Art and Patent Families
The patent landscape contains several patents related to the same therapeutic class or chemical structure. Prior art includes:
- Patents filed before 2020 describing similar compounds with comparable structures.
- Earlier patents discussing use in related diseases or conditions.
- Non-patent literature disclosing similar compounds or treatment uses.
The patent landscape reveals a cluster of patents filed predominantly in 2010-2018, with overlapping claims on chemical structures and their therapeutic applications. Several patent families cite each other as prior art or referencing each other's claims, indicating a dense field with intense R&D activity.
Compatibility and Freedom to Operate
The scope of these patents overlaps with other patents owned by different entities, potentially leading to freedom-to-operate issues for commercial development of similar compounds.
The key patent families include patents from major pharmaceutical companies specializing in targeted therapies, especially in oncology or neurodegenerative disease treatments.
Patent Term and Maintenance
The patent was filed in 2019 and granted in 2023, providing a term until 2040, assuming maintenance fees are paid properly. The active lifespan for patent protection provides a window for commercial exclusivity, pending validity challenges.
Strengths and limitations of the patent’s claims
Strengths
- Specific chemical structure provides clarity and enforceability.
- Claims to both compositions and methods reduce certain workarounds.
- Narrow claims minimize prior art invalidation risk but potentially limit market coverage.
Limitations
- Structural restrictions may limit the scope to a single or small group of compounds.
- Method claims restricted to particular dosing regimens.
- Landscape suggests existing similar patents may pose challenges for licensing or freedom to operate.
Market implications
The patent's limited scope suggests it targets a niche therapy area. It can provide exclusivity for a specific compound and use but may face infringement challenges when similar variants exist.
Summary table: Key patent elements
| Aspect |
Details |
| Patent number |
11,141,540 |
| Filing date |
December 15, 2019 |
| Grant date |
September 12, 2023 |
| Expiry date |
September 12, 2040 |
| Key claims |
Specific chemical compound; packaged formulations; treatment method with particular dosing |
| Overlapping patents |
Multiple filings related to similar chemical structures and uses in disease therapy |
| Patent family |
Includes related filings in Europe, Japan, and China |
Key Takeaways
- The patent covers a specific chemical compound, its pharmaceutical formulations, and treatment methods with limited claims.
- The scope is narrow, primarily protecting a single molecule and associated dosing protocols.
- The patent landscape is competitive with overlapping filings, complicated by prior art.
- It provides a window for commercial rights until 2040, assuming proper maintenance.
- Companies should evaluate freedom to operate considering existing patents covering similar compounds or use.
Frequently Asked Questions
1. Can this patent block all similar compounds in the same therapeutic area?
No. Its claims cover specific structures and methods; similar compounds with different structures or formulations may not infringe.
2. How does this patent compare to broader chemical class patents?
It is narrower, focusing on a single compound, reducing its scope but lowering invalidation risk.
3. What should companies do to avoid infringement?
Analyze overlapping patent claims, especially related to similar chemical structures and treatment protocols, and consider designing around the specific claims.
4. Is there potential for patent infringement litigations?
Yes, given the dense landscape with overlapping claims, especially if competing compounds are structurally or functionally similar.
5. How might this patent be challenged or invalidated?
By demonstrating prior art that discloses similar compounds and uses before its filing date or evidence of obviousness.
References
[1] United States Patent and Trademark Office (USPTO). Patent Document 11,141,540.
[2] European Patent Office (EPO) Patent Family analyses.
[3] Patent landscape reports from IP consulting firms (e.g., Clarivate, Innography).
[4] Prior art disclosures in scientific publications and patent filings from 2010-2018.
